Citigroup’s Arena Pharmaceuticals Inc ARNA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q1 | – | Sell |
-4,300
| Closed | -$330K | – | 7762 |
|
|
2020
Q4 | $330K | Sell |
4,300
-400
| -9% | -$30K | ﹤0.01% | 4581 |
|
|
2020
Q3 | $352K | Sell |
4,700
-24,400
| -84% | -$1.63M | ﹤0.01% | 4159 |
|
|
2020
Q2 | $1.83M | Buy |
29,100
+26,500
| +1,019% | +$1.46M | ﹤0.01% | 2910 |
|
|
2020
Q1 | $109K | Sell |
2,600
-27,300
| -91% | -$1.25M | ﹤0.01% | 5276 |
|
|
2019
Q4 | $1.36M | Sell |
29,900
-1,600
| -5% | -$75.6K | ﹤0.01% | 3425 |
|
|
2019
Q3 | $1.44M | Buy |
31,500
+13,400
| +74% | +$753K | ﹤0.01% | 3233 |
|
|
2019
Q2 | $1.06M | Sell |
18,100
-1,400
| -7% | -$72.4K | ﹤0.01% | 3549 |
|
|
2019
Q1 | $874K | Sell |
19,500
-26,000
| -57% | -$1.19M | ﹤0.01% | 3555 |
|
|
2018
Q4 | $1.77M | Buy |
45,500
+5,700
| +14% | +$224K | ﹤0.01% | 2781 |
|
|
2018
Q3 | $1.83M | Buy |
39,800
+15,000
| +60% | +$608K | ﹤0.01% | 2826 |
|
|
2018
Q2 | $1.08M | Sell |
24,800
-62,300
| -72% | -$2.68M | ﹤0.01% | 3278 |
|
|
2018
Q1 | $3.44M | Buy |
87,100
+70,200
| +415% | +$2.73M | ﹤0.01% | 2119 |
|
|
2017
Q4 | $574K | Sell |
16,900
-5,800
| -26% | -$165K | ﹤0.01% | 3963 |
|
|
2017
Q3 | $579K | Buy |
+22,700
| New | +$521K | ﹤0.01% | 3970 |
|
|
2017
Q2 | – | Sell |
-250
| Closed | -$4K | – | 7555 |
|
|
2017
Q1 | $4K | Sell |
250
-1,710
| -87% | -$25.3K | ﹤0.01% | 6880 |
|
|
2016
Q4 | $28K | Buy |
1,960
+870
| +80% | +$13.5K | ﹤0.01% | 6403 |
|
|
2016
Q3 | $19K | Buy |
1,090
+720
| +195% | +$11.9K | ﹤0.01% | 6244 |
|
|
2016
Q2 | $6K | Buy |
370
+190
| +106% | +$3.4K | ﹤0.01% | 6738 |
|
|
2016
Q1 | $4K | Sell |
180
-320
| -64% | -$5.13K | ﹤0.01% | 7094 |
|
|
2015
Q4 | $10K | Sell |
500
-220
| -31% | -$4.49K | ﹤0.01% | 6830 |
|
|
2015
Q3 | $14K | Buy |
720
+130
| +22% | +$4.42K | ﹤0.01% | 6269 |
|
|
2015
Q2 | $27K | Buy |
+590
| New | +$25.6K | ﹤0.01% | 5938 |
|
Citigroup's ARNA Position: Q1 2022 in Review
Citigroup sold out of Arena Pharmaceuticals Inc (ARNA) in Q1 2022, closing a stake of 352,641 shares — an estimated $32.8M sold.
Citigroup first reported a position in ARNA in Q2 2013 and held it in 35 quarters. The position peaked at $32.8M in Q4 2021. 1 fund tracked by Wall St. Rank holds ARNA as of Q1 2022.
- Citigroup reported no remaining Arena Pharmaceuticals Inc position as of Q1 2022 after selling out during the quarter.
- Citigroup sold 352,641 Arena Pharmaceuticals Inc shares in Q1 2022, an estimated $32.8M.
- Citigroup first reported a position in Arena Pharmaceuticals Inc in Q2 2013 and held it in 35 quarters.
- Citigroup's Arena Pharmaceuticals Inc position peaked at $32.8M in Q4 2021.
- 1 fund tracked by Wall St. Rank held Arena Pharmaceuticals Inc as of Q1 2022.
Based on Citigroup's 13F filing for Q1 2022, filed 12 May 2022.